A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression

Immune-checkpoint blockade (ICB) therapy has changed the clinical outcome of many types of aggressive tumors, but there still remain many cancer patients that do not respond to these treatments. There is an unmet need to develop a feasible clinical therapeutic platform to increase the rate of respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Meraviglia-Crivelli, Daniel, Villanueva, Helena, Menon, Ashwathi Puravankara, Zheleva, Angelina, Moreno, Beatriz, Villalba-Esparza, María, Pastor, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379514/
https://www.ncbi.nlm.nih.gov/pubmed/35991316
http://dx.doi.org/10.1016/j.omtn.2022.07.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379514/
https://www.ncbi.nlm.nih.gov/pubmed/35991316
http://dx.doi.org/10.1016/j.omtn.2022.07.017

Ejemplares similares